Una candidatura completa in un minuto
Curriculum e lettera di presentazione personalizzati, pronti da inviare.
GSK seeks a Principal Scientist in Cheminformatics to develop and embed advanced computational methods and predictive models to accelerate medicines discovery. You will work with large proprietary datasets and integrate outputs into decision-making workflows.
The role focuses on ML, cheminformatics and computational chemistry, with prototypes blending LLM-based reasoning with scientific tools and data to speed hypothesis generation and design cycles.
The Principal Scientist role (within the Cheminformatics group) uses large proprietary internal datasets to develop, integrate and embed advanced computational methods and predictive in-silico models to accelerate the discovery of medicines. With a focus on machine learning, cheminformatics and computational chemistry methodologies, you will help drive the development and delivery of key new capabilities for our internal automated small molecule design platform coupled directly to lab automation.
Location: This role will temporarily be based at Stevenage. However, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge UK, in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029.
This role is a great opportunity to be instrumental in developing and delivering subject matter expertise across GSK. As this role is multi-faceted and includes collaborating / liaising with a wide variety of stakeholders and matrix teams you must have strong experience of working in complex technical situations, with demonstrable clear problem-solving approach to your work. Strong people skills and a proven ability to influence people to achieve and drive performance are also pre-requisites for this role.
GSK remains committed to achieving bold commercial ambitions for the future. By 2031, we aim to deliver £40 billion in annual sales, leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patients globally. Our Ahead Together strategy is centered on early intervention to prevent and alter the course of disease, thereby protecting people and supporting healthcare systems. Our diverse portfolio consists of vaccines, specialty medicines, and general medicines. Through continuous innovation and a dedicated focus on scientific and technical excellence, we strive to develop and launch new, groundbreaking treatments that address critical health challenges.
APPLICATION CLOSING DATE - Friday 20 th of November 2026 (COB).
Artificial Intelligence (AI), C